Squarepoint Ops LLC Has $16.06 Million Stake in Scholar Rock Holding Corporation $SRRK

Posted by Brenda Bartman on Sep 10th, 2026

Squarepoint Ops LLC increased its stake in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK – Free Report) by 484.5% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 291,996 shares of the company’s stock after buying an additional 242,041 shares during the quarter. Squarepoint Ops LLC’s holdings in Scholar Rock were worth $16,060,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of Scholar Rock by 20.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,406 shares of the company’s stock valued at $77,000 after buying an additional 242 shares during the period. Values First Advisors Inc. raised its holdings in shares of Scholar Rock by 1.5% during the first quarter. Values First Advisors Inc. now owns 18,850 shares of the company’s stock worth $927,000 after acquiring an additional 286 shares in the last quarter. IFP Advisors Inc raised its holdings in shares of Scholar Rock by 294.1% during the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after acquiring an additional 450 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Scholar Rock by 151.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after purchasing an additional 525 shares during the last quarter. Finally, California State Teachers Retirement System grew its stake in Scholar Rock by 0.9% in the second quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock valued at $2,209,000 after purchasing an additional 577 shares in the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Insider Activity at Scholar Rock

In other news, Director Katie Peng sold 5,446 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $53.88, for a total transaction of $293,430.48. Following the sale, the director directly owned 34,301 shares in the company, valued at approximately $1,848,137.88. The trade was a 13.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael Gilman sold 2,544 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $53.87, for a total value of $137,045.28. Following the completion of the transaction, the director owned 59,511 shares of the company’s stock, valued at $3,205,857.57. The trade was a 4.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 17,149 shares of company stock worth $923,108 in the last three months. Company insiders own 10.30% of the company’s stock.

Analyst Ratings Changes

SRRK has been the subject of a number of recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Scholar Rock in a research note on Thursday, June 18th. Citigroup increased their price objective on Scholar Rock from $58.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, August 7th. JPMorgan Chase & Co. raised their price objective on shares of Scholar Rock from $56.00 to $63.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a research note on Friday, July 17th. Finally, HC Wainwright cut shares of Scholar Rock from a “buy” rating to a “neutral” rating in a report on Tuesday. Four analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $58.77.

Get Our Latest Analysis on SRRK

Scholar Rock Stock Down 4.9%

SRRK opened at $54.62 on Thursday. The stock has a market capitalization of $6.65 billion, a price-to-earnings ratio of -15.83 and a beta of 0.67. Scholar Rock Holding Corporation has a 1-year low of $27.07 and a 1-year high of $61.76. The business has a 50 day moving average of $53.53 and a 200-day moving average of $49.42. The company has a current ratio of 7.02, a quick ratio of 7.02 and a debt-to-equity ratio of 0.77.

Scholar Rock (NASDAQ:SRRK – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.84). During the same quarter in the prior year, the company posted ($0.98) EPS. As a group, sell-side analysts anticipate that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current year.

Scholar Rock Company Profile

(Free Report)

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).